Top

Published in:

Open Access 01-09-2020 | Infliximab | Review

Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review

Authors: Mourad F. Rezk, Burkhard Pieper

Published in: Advances in Therapy | Issue 9/2020

Abstract

Immune-mediated inflammatory diseases (IMIDs) are chronic conditions that create a significant disease burden on millions of patients while adding a major financial burden to societies and healthcare systems.

The introduction of biologic medicines has contributed majorly to improving the clinical outcomes of IMIDs and as such these modalities have gained first- or second-line positions in a wide range of treatment guidelines from different international clinical societies. However, the high cost of these biologics traditionally limited their accessibility and delayed their initiation, leaving millions of patients with unmet medical needs for a more affordable and sustainable solution.

The introduction of cost-efficient biosimilar anti-TNFs within Europe since 2013 has allowed more patients with IMIDs to access biologic therapies earlier and for longer, potentially altering the course of the disease into a milder phenotype and reducing the long-term disease burden. This review provides the latest evidence for the impact of biosimilars on patient outcomes and demonstrates their clinical value beyond a reduction in price.

Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251–60. https://doi.org/10.1136/pgmj.2006.052688.CrossRefPubMedPubMedCentral

El-Gabalawy H, Guenther LC, Bernstein CN. Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl. 2010;85:2–10. https://doi.org/10.3899/jrheum.091461.CrossRefPubMed

Burisch J, Jess T, Martinato M, Lakatos PL, EpiCom E. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7(4):322–37. https://doi.org/10.1016/j.crohns.2013.01.010.CrossRefPubMed

Griffiths CEM, Jo SJ, Naldi L, et al. A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. Br J Dermatol. 2018;179(1):173–81. https://doi.org/10.1111/bjd.16332.CrossRefPubMed

Jacobs P, Bissonnette R, Guenther LC. Socioeconomic burden of immune-mediated inflammatory diseases—focusing on work productivity and disability. J Rheumatol Suppl. 2011;88:55–61. https://doi.org/10.3899/jrheum.110901.CrossRefPubMed

Cote-Daigneault J, Bouin M, Lahaie R, Colombel JF, Poitras P. Biologics in inflammatory bowel disease: what are the data? United Eur Gastroenterol J. 2015;3(5):419–28. https://doi.org/10.1177/2050640615590302.CrossRef

Law ST, Taylor PC. Role of biological agents in treatment of rheumatoid arthritis. Pharmacol Res. 2019;150:104497. https://doi.org/10.1016/j.phrs.2019.104497.CrossRefPubMed

Rein P, Mueller RB. Treatment with biologicals in rheumatoid arthritis: an overview. Rheumatol Ther. 2017;4(2):247–61. https://doi.org/10.1007/s40744-017-0073-3.CrossRefPubMedPubMedCentral

Ronholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18:2297. https://doi.org/10.3390/ijms18112297.CrossRefPubMedCentral

10.

Leonardi CL, Romiti R, Tebbey PW. Ten years on: the impact of biologics on the practice of dermatology. Dermatol Clin. 2015;33(1):111–25. https://doi.org/10.1016/j.det.2014.09.009.CrossRefPubMed

11.

Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–15. https://doi.org/10.1016/j.jaad.2007.09.010.CrossRefPubMed

12.

Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999;130(6):478–86. https://doi.org/10.7326/0003-4819-130-6-199903160-00004.CrossRefPubMed

13.

Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340(4):253–9. https://doi.org/10.1056/NEJM199901283400401.CrossRefPubMed

14.

Nurmohamed M, Choy E, Lula S, Kola B, DeMasi R, Accossato P. The impact of biologics and tofacitinib on cardiovascular risk factors and outcomes in patients with rheumatic disease: a systematic literature review. Drug Saf. 2018;41(5):473–88. https://doi.org/10.1007/s40264-017-0628-9.CrossRefPubMedPubMedCentral

15.

Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxford). 2012;51(Suppl 6):vi37–43. https://doi.org/10.1093/rheumatology/kes283.CrossRef

16.

Iskandar IYK, Ashcroft DM, Warren RB, et al. Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. Br J Dermatol. 2017;177(5):1410–21. https://doi.org/10.1111/bjd.15531.CrossRefPubMedPubMedCentral

17.

LeBlanc K, Mosli MH, Parker CE, MacDonald JK. The impact of biological interventions for ulcerative colitis on health-related quality of life. Cochrane Database Syst Rev. 2015:CD008655. https://doi.org/10.1002/14651858.cd008655.pub3.

18.

Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs. 2010;70(2):121–45. https://doi.org/10.2165/11531980-000000000-00000.CrossRefPubMed

19.

Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499–510. https://doi.org/10.1136/annrheumdis-2015-208337.CrossRefPubMed

20.

Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–84. https://doi.org/10.1093/ecco-jcc/jjx009.CrossRefPubMed

21.

Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113(4):481–517. https://doi.org/10.1038/ajg.2018.27.CrossRefPubMed

22.

Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72. https://doi.org/10.1016/j.jaad.2018.11.057.CrossRefPubMed

23.

Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris—update 2015–short version–EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277–94. https://doi.org/10.1111/jdv.13354.CrossRefPubMed

24.

Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413. https://doi.org/10.14309/ajg.0000000000000152.CrossRefPubMed

25.

Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5–32. https://doi.org/10.1002/art.40726.CrossRefPubMed

26.

Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26. https://doi.org/10.1002/art.39480.CrossRefPubMed

27.

Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–99. https://doi.org/10.1136/annrheumdis-2019-216655.CrossRefPubMed

28.

Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22. https://doi.org/10.1093/ecco-jcc/jjz180.CrossRefPubMed

29.

van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978–91. https://doi.org/10.1136/annrheumdis-2016-210770.CrossRefPubMed

30.

Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599–613. https://doi.org/10.1002/art.41042.CrossRefPubMedPubMedCentral

31.

Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs. 2005;65(5):661–94. https://doi.org/10.2165/00003495-200565050-00006.CrossRefPubMed

32.

Pillai N, Dusheiko M, Burnand B, Pittet V. A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS One. 2017;12(10):e0185500. https://doi.org/10.1371/journal.pone.0185500.CrossRefPubMedPubMedCentral

33.

van der Velde G, Pham B, Machado M, et al. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken). 2011;63(1):65–78. https://doi.org/10.1002/acr.20338.CrossRef

34.

IQVIA. Global, European and Belgian pharmaceutical market trends. 2019. Available from: https://www.cib-pharma.be/uploads/global-european-and-belgian-pharmaceutical-market-trends-2019-final1552840137.pdf. Accessed 4 May 2020.

35.

Gottlieb S. Don’t give up on biosimilars-congress can give them a boost: drugs grown in live cells are hard to replicate. But policy changes can help accelerate the process. Am Health Drug Benefits. 2019;12(5):252–3.PubMedPubMedCentral

36.

Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol. 2019;10:279. https://doi.org/10.3389/fphar.2019.00279.CrossRefPubMedPubMedCentral

37.

Dutta B, Huys I, Vulto AG, Simoens S. Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price! BioDrugs. 2020;34(2):159–70. https://doi.org/10.1007/s40259-019-00395-w.CrossRefPubMed

38.

Inotai A, Csanadi M, Petrova G, et al. Patient access, unmet medical need, expected benefits, and concerns related to the utilisation of biosimilars in Eastern European countries: a survey of experts. Biomed Res Int. 2018;2018:9597362. https://doi.org/10.1155/2018/9597362.CrossRefPubMedPubMedCentral

39.

Kalo Z, Voko Z, Ostor A, et al. Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region. J Mark Access Health Policy. 2017;5(1):1345580. https://doi.org/10.1080/20016689.2017.1345580.CrossRefPubMedPubMedCentral

40.

McBride A, Balu S, Campbell K, Bikkina M, MacDonald K, Abraham I. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. Future Oncol. 2017;13(25):2285–95. https://doi.org/10.2217/fon-2017-0374.CrossRefPubMed

41.

Uhlig T, Goll GL. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. Rheumatology (Oxford). 2017;56(suppl_4):iv49–62. https://doi.org/10.1093/rheumatology/kex276.CrossRef

42.

IQVIA. The impact of biosimilar competition in Europe. 2018. https://ec.europa.eu/docsroom/documents/31642. Accessed 4 May 2020.

43.

Bergstra SA, Branco JC, Vega-Morales D, et al. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry. Ann Rheum Dis. 2018;77(10):1413–20. https://doi.org/10.1136/annrheumdis-2018-213289.CrossRefPubMed

44.

Pentek M, Lakatos PL, Oorsprong T, et al. Access to biologicals in Crohn’s disease in ten European countries. World J Gastroenterol. 2017;23(34):6294–305. https://doi.org/10.3748/wjg.v23.i34.6294.CrossRefPubMedPubMedCentral

45.

Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198–206. https://doi.org/10.1136/annrheumdis-2012-202603.CrossRefPubMed

46.

Kawalec P, Stawowczyk E, Tesar T, et al. Pricing and reimbursement of biosimilars in central and Eastern European countries. Front Pharmacol. 2017;8:288. https://doi.org/10.3389/fphar.2017.00288.CrossRefPubMedPubMedCentral

47.

Zielinska J, Baialik W. Recent changes on the biopharmaceutical market after the introduction of biosimilar G-CSF products. Oncol Clin Pract. 2016;12:144–52.

48.

Gascon P, Tesch H, Verpoort K, et al. Clinical experience with Zarzio® in Europe: what have we learned? Support Care Cancer. 2013;21(10):2925–32. https://doi.org/10.1007/s00520-013-1911-7.CrossRefPubMedPubMedCentral

49.

Cornes P, Gascon P, Vulto AG, Aapro M. Biosimilar pegfilgrastim: improving access and optimising practice to supportive care that enables cure. BioDrugs. 2020;34(3):255–63. https://doi.org/10.1007/s40259-020-00411-4.CrossRefPubMedPubMedCentral

50.

Di Giuseppe D, Frisell T, Ernestam S, et al. Uptake of rheumatology biosimilars in the absence of forced switching. Expert Opin Biol Ther. 2018;18(5):499–504. https://doi.org/10.1080/14712598.2018.1458089.CrossRefPubMed

51.

Razanskaite V, Bettey M, Downey L, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017;11(6):690–6. https://doi.org/10.1093/ecco-jcc/jjw216.CrossRefPubMed

52.

Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis. 2004;63(6):627–33. https://doi.org/10.1136/ard.2003.011395.CrossRefPubMedPubMedCentral

53.

Kang B, Choe YH. Early biologic treatment in pediatric Crohn’s disease: catching the therapeutic window of opportunity in early disease by treat-to-target. Pediatr Gastroenterol Hepatol Nutr. 2018;21(1):1–11. https://doi.org/10.5223/pghn.2018.21.1.1.CrossRefPubMedPubMedCentral

54.

Monti S, Montecucco C, Bugatti S, Caporali R. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open. 2015;1(Suppl 1):e000057. https://doi.org/10.1136/rmdopen-2015-000057.CrossRefPubMedPubMedCentral

55.

Nagy G, van Vollenhoven RF. Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now? Arthritis Res Ther. 2015;17:181. https://doi.org/10.1186/s13075-015-0707-1.CrossRefPubMedPubMedCentral

56.

Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol. 2003;21(5 Suppl 31):S154–7.PubMed

57.

van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010;62(12):3537–46. https://doi.org/10.1002/art.27692.CrossRefPubMed

58.

van Nies JA, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AH. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann Rheum Dis. 2015;74(5):806–12. https://doi.org/10.1136/annrheumdis-2014-206047.CrossRefPubMed

59.

Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum. 2006;55(6):864–72. https://doi.org/10.1002/art.22353.CrossRefPubMed

60.

Baranauskaite A, Raffayova H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012;71(4):541–8. https://doi.org/10.1136/ard.2011.152223.CrossRefPubMed

61.

Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95. https://doi.org/10.1056/NEJMoa0904492.CrossRefPubMed

62.

D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371(9613):660–7. https://doi.org/10.1016/S0140-6736(08)60304-9.CrossRefPubMed

63.

Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375–82. https://doi.org/10.1016/S0140-6736(08)61000-4.CrossRefPubMed

64.

Kavanaugh A, Keystone E, Greenberg JD, et al. Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registry. Rheumatology (Oxford). 2017;56(7):1095–101. https://doi.org/10.1093/rheumatology/kex042.CrossRef

65.

Rubin DT, Uluscu O, Sederman R. Response to biologic therapy in Crohn’s disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis. 2012;18(12):2225–31. https://doi.org/10.1002/ibd.22925.CrossRefPubMed

66.

St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432–43. https://doi.org/10.1002/art.20568.CrossRefPubMed

67.

Ungaro RC, Aggarwal S, Topaloglu O, Lee WJ, Clark R, Colombel JF. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn’s disease. Aliment Pharmacol Ther. 2020;51(9):831–42. https://doi.org/10.1111/apt.15685.CrossRefPubMedPubMedCentral

68.

van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, et al. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis. 2009;68(7):1153–8. https://doi.org/10.1136/ard.2008.093294.CrossRefPubMed

69.

Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77. https://doi.org/10.1136/annrheumdis-2016-210715.CrossRefPubMed

70.

Batko B, Batko K, Krzanowski M, Zuber Z. Physician adherence to treat-to-target and practice guidelines in rheumatoid arthritis. J Clin Med. 2019;8(9):1416. https://doi.org/10.3390/jcm8091416.CrossRefPubMedCentral

71.

Jackson BD, Con D, Liew D, De Cruz P. Clinicians’ adherence to international guidelines in the clinical care of adults with inflammatory bowel disease. Scand J Gastroenterol. 2017;52(5):536–42. https://doi.org/10.1080/00365521.2017.1278785.CrossRefPubMed

72.

Lesuis N, den Broeder AA, Hulscher ME, van Vollenhoven RF. Practice what you preach? An exploratory multilevel study on rheumatoid arthritis guideline adherence by rheumatologists. RMD Open. 2016;2(1):e000195. https://doi.org/10.1136/rmdopen-2015-000195.CrossRefPubMedPubMedCentral

73.

National Institute for Health and Care Excellence. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. Technology appraisal guidance, 26 January 2016. https://www.nice.org.uk/guidance/ta375/resources/adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-rheumatoid-arthritis-not-previously-treated-with-dmards-or-after-conventional-dmards-only-have-failed-pdf-82602790920133. Accessed 4 May 2020.

74.

National Institute for Health and Care Excellence. Review of TA375; Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. Technology appraisal review proposal paper. January 2019. https://www.nice.org.uk/guidance/ta375/resources/consultation-review-may-2019-pdf-8786049415621. Accessed 4 May 2020.

75.

Haugeberg G, Boyesen P, Helgetveit K, Proven A. Clinical and radiographic outcomes in patients diagnosed with early rheumatoid arthritis in the first years of the biologic treatment era: a 10-year prospective observational study. J Rheumatol. 2015;42(12):2279–87. https://doi.org/10.3899/jrheum.150384.CrossRefPubMed

76.

Mao EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther. 2017;45(1):3–13. https://doi.org/10.1111/apt.13847.CrossRefPubMed

77.

Nam JL, Emery P. Is there a place for initial treatment with biological DMARDs in the early phase of RA? Best Pract Res Clin Rheumatol. 2013;27:537–54. https://doi.org/10.1016/j.berh.2013.09.003CrossRefPubMed

78.

Patel D, Shelbaya A, Cheung R, Aggarwal J, Park SH, Coindreau J. Cost-effectiveness of early treatment with originator biologics or their biosimilars after methotrexate failure in patients with established rheumatoid arthritis. Adv Ther. 2019;36(8):2086–95. https://doi.org/10.1007/s12325-019-00986-7.CrossRefPubMedPubMedCentral

79.

Verdecchia P, Staessen JA, Angeli F, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009;374(9689):525–33. https://doi.org/10.1016/S0140-6736(09)61340-4.CrossRefPubMed

80.

Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–53. https://doi.org/10.1056/NEJMoa052187.CrossRefPubMed

81.

van Vollenhoven R. Treat-to-target in rheumatoid arthritis—are we there yet? Nat Rev Rheumatol. 2019;15(3):180–6. https://doi.org/10.1038/s41584-019-0170-5.CrossRefPubMed

82.

Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290–8. https://doi.org/10.1016/j.jaad.2016.10.017.CrossRefPubMed

83.

Drescher H, Lissoos T, Hajisafari E, Evans ER. Treat-to-target approach in inflammatory bowel disease: the role of advanced practice providers. J Nurse Pract. 2019;15:676–81. https://doi.org/10.1016/j.nurpra.2019.07.015CrossRef

84.

Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15. https://doi.org/10.1136/annrheumdis-2015-207524.CrossRefPubMed

85.

Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263–9. https://doi.org/10.1016/S0140-6736(04)16676-2.CrossRefPubMed

86.

Hughes CD, Scott DL, Ibrahim F, TITRATE Programme Investigators. Intensive therapy and remissions in rheumatoid arthritis: a systematic review. BMC Musculoskelet Disord. 2018;19(1):389. https://doi.org/10.1186/s12891-018-2302-5.CrossRefPubMedPubMedCentral

87.

Merola JF, Perez Chada L, Siegel M, et al. The National Psoriasis Foundation psoriasis treatment targets in real world patients: prevalence and association with patient reported outcomes in the Corrona Psoriasis Registry. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16274.CrossRefPubMedPubMedCentral

88.

Schipper LG, van Hulst LT, Grol R, van Riel PL, Hulscher ME, Fransen J. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford). 2010;49(11):2154–64. https://doi.org/10.1093/rheumatology/keq195.CrossRef

89.

Stoffer MA, Schoels MM, Smolen JS, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis. 2016;75(1):16–22. https://doi.org/10.1136/annrheumdis-2015-207526.CrossRefPubMed

90.

Ten Klooster PM, Oude Voshaar MAH, Fakhouri W, de la Torre I, Nicolay C, van de Laar M. Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy. Clin Rheumatol. 2019;38(10):2727–36. https://doi.org/10.1007/s10067-019-04600-7.CrossRefPubMed

91.

Gvozdenovic E, Allaart CF, van der Heijde D, et al. When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the international recommendation implementation study (IRIS). RMD Open. 2016;2(1):e000221. https://doi.org/10.1136/rmdopen-2015-000221.CrossRefPubMedPubMedCentral

92.

Harrold LR, Harrington JT, Curtis JR, et al. Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. Arthritis Rheum. 2012;64(3):630–8. https://doi.org/10.1002/art.33380.CrossRefPubMedPubMedCentral

93.

Pappas DA, Gerber RA, Litman HJ, et al. Delayed treatment acceleration in patients with rheumatoid arthritis who have inadequate response to initial tumor necrosis factor inhibitors: data from the Corrona Registry. Am Health Drug Benefits. 2018;11(3):148–58.PubMedPubMedCentral

94.

Yu Z, Lu B, Agosti J, et al. Implementation of treat-to-target for rheumatoid arthritis in the US: analysis of baseline data from a randomized controlled trial. Arthritis Care Res (Hoboken). 2018;70(5):801–6. https://doi.org/10.1002/acr.23343.CrossRef

95.

Littlejohn G, Roberts L, Arnold M, et al. A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control. Int J Rheum Dis. 2013;16(5):532–8. https://doi.org/10.1111/1756-185X.12163.CrossRefPubMed

96.

Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45(10):1291–302. https://doi.org/10.1111/apt.14030.CrossRefPubMedPubMedCentral

97.

Emamikia S, Arkema EV, Gyori N, et al. Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials. RMD Open. 2016;2(2):e000323. https://doi.org/10.1136/rmdopen-2016-000323.CrossRefPubMedPubMedCentral

98.

Erichsen CY, Jensen P, Kofoed K. Biologic therapies targeting the interleukin (IL)-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020;34(1):30–8. https://doi.org/10.1111/jdv.15879.CrossRefPubMed

99.

Gisondi P, Di Mercurio M, Idolazzi L, Girolomoni G. Concept of remission in chronic plaque psoriasis. J Rheumatol Suppl. 2015;93:57–60. https://doi.org/10.3899/jrheum.150638.CrossRefPubMed

100.

Pavelka K, Akkoc N, Al-Maini M, et al. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access. Rheumatol Int. 2017;37(9):1469–79. https://doi.org/10.1007/s00296-017-3749-7.CrossRefPubMed

101.

Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. 2013;381(9870):918–29. https://doi.org/10.1016/S0140-6736(12)61811-X.CrossRefPubMed

102.

van Vollenhoven RF, Ostergaard M, Leirisalo-Repo M, et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis. 2016;75(1):52–8. https://doi.org/10.1136/annrheumdis-2014-205726.CrossRefPubMed

103.

Chen MH, Lee MH, Liao HT, Chen WS, Lai CC, Tsai CY. Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment. Clin Rheumatol. 2018;37(2):429–38. https://doi.org/10.1007/s10067-017-3965-2.CrossRefPubMed

104.

Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis. 2012;18(1):174–9. https://doi.org/10.1002/ibd.21792.CrossRefPubMed

105.

Edwards CJ, Fautrel B, Schulze-Koops H, Huizinga TWJ, Kruger K. Dosing down with biologic therapies: a systematic review and clinicians’ perspective. Rheumatology (Oxford). 2017;56(11):1847–56. https://doi.org/10.1093/rheumatology/kew464.CrossRef

106.

Haschka J, Englbrecht M, Hueber AJ, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2016;75(1):45–51. https://doi.org/10.1136/annrheumdis-2014-206439.CrossRefPubMed

107.

Huang YW, Tsai TF. Remission duration and long-term outcomes in patients with moderate-to-severe psoriasis treated by biologics or tofacitinib in controlled clinical trials: a 15-year single-center experience. Dermatol Ther (Heidelb). 2019;9(3):553–69. https://doi.org/10.1007/s13555-019-0310-5.CrossRef

108.

Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019;44(4):495–507. https://doi.org/10.1111/jcpt.12830.CrossRefPubMed

109.

Kuijper TM, Lamers-Karnebeek FB, Jacobs JW, Hazes JM, Luime JJ. Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review. J Rheumatol. 2015;42(11):2012–22. https://doi.org/10.3899/jrheum.141520.CrossRefPubMed

110.

Simonini G, Ferrara G, Pontikaki I, et al. Flares after withdrawal of biologic therapies in juvenile idiopathic arthritis: clinical and laboratory correlates of remission duration. Arthritis Care Res (Hoboken). 2018;70(7):1046–51. https://doi.org/10.1002/acr.23435.CrossRef

111.

Torres J, Boyapati RK, Kennedy NA, Louis E, Colombel JF, Satsangi J. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology. 2015;149(7):1716–30. https://doi.org/10.1053/j.gastro.2015.08.055.CrossRefPubMed

112.

Ye W, Tucker LJ, Coates LC. Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity. Drugs. 2018;78(16):1705–15. https://doi.org/10.1007/s40265-018-0994-3.CrossRefPubMed

113.

Doherty G, Katsanos KH, Burisch J, et al. European Crohn’s and Colitis Organisation topical review on treatment withdrawal [‘exit strategies’] in inflammatory bowel disease. J Crohns Colitis. 2018;12(1):17–31. https://doi.org/10.1093/ecco-jcc/jjx101.CrossRefPubMed

114.

Schlager L, Loiskandl M, Aletaha D, Radner H. Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. Rheumatology (Oxford). 2020;59(2):324–34. https://doi.org/10.1093/rheumatology/kez278.CrossRef

115.

Sekiguchi M, Fujii T, Matsui K, et al. Differences in predictive factors for sustained clinical remission with abatacept between younger and elderly patients with biologic-naive rheumatoid arthritis: results from the ABROAD study. J Rheumatol. 2016;43(11):1974–83. https://doi.org/10.3899/jrheum.160051.CrossRefPubMed

116.

Valor L, Garrido J, Martinez-Estupinan L, et al. Identifying markers of sustained remission in rheumatoid arthritis patients on long-term tapered biological disease-modifying antirheumatic drugs. Rheumatol Int. 2018;38(8):1465–70. https://doi.org/10.1007/s00296-018-4087-0.CrossRefPubMed

117.

Schieir O, Tosevski C, Glazier RH, Hogg-Johnson S, Badley EM. Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis. Ann Rheum Dis. 2017;76(8):1396–404. https://doi.org/10.1136/annrheumdis-2016-210275.CrossRefPubMed

118.

Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073–113. https://doi.org/10.1016/j.jaad.2018.11.058.CrossRefPubMed

119.

Aletaha D, Epstein AJ, Skup M, Zueger P, Garg V, Panaccione R. Risk of developing additional immune-mediated manifestations: a retrospective matched cohort study. Adv Ther. 2019;36(7):1672–83. https://doi.org/10.1007/s12325-019-00964-z.CrossRefPubMedPubMedCentral

120.

Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005;129(3):827–36. https://doi.org/10.1053/j.gastro.2005.06.021.CrossRefPubMed

121.

Burisch J, Jess T, Egeberg A. Incidence of immune-mediated inflammatory diseases among patients with inflammatory bowel diseases in Denmark. Clin Gastroenterol Hepatol. 2019;17(13):2704–12. https://doi.org/10.1016/j.cgh.2019.03.040.CrossRefPubMed

122.

Cohen R, Robinson D Jr, Paramore C, Fraeman K, Renahan K, Bala M. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001–2002. Inflamm Bowel Dis. 2008;14(6):738–43. https://doi.org/10.1002/ibd.20406.CrossRefPubMed

123.

Conway G, Velonias G, Andrews E, Garber JJ, Yajnik V, Ananthakrishnan AN. The impact of co-existing immune-mediated diseases on phenotype and outcomes in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;45(6):814–23. https://doi.org/10.1111/apt.13940.CrossRefPubMedPubMedCentral

124.

Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244–50. https://doi.org/10.1001/archdermatol.2012.2502.CrossRefPubMed

125.

Aladul MI, Fitzpatrick RW, Chapman SR. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: results of a budget impact analysis. Res Social Adm Pharm. 2019;15(3):310–7. https://doi.org/10.1016/j.sapharm.2018.05.009.CrossRefPubMed

126.

Jha A, Upton A, Dunlop WC, Akehurst R. The budget impact of biosimilar infliximab (Remsima®) for the treatment of autoimmune diseases in five European countries. Adv Ther. 2015;32(8):742–56. https://doi.org/10.1007/s12325-015-0233-1.CrossRefPubMedPubMedCentral

127.

Brodszky V, Rencz F, Pentek M, Baji P, Lakatos PL, Gulacsi L. A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):119–25. https://doi.org/10.1586/14737167.2015.1067142.CrossRefPubMed

128.

Lee SM, Jung JH, Suh D, et al. Budget impact of switching to biosimilar trastuzumab (CT-P6) for the treatment of breast cancer and gastric cancer in 28 European countries. BioDrugs. 2019;33(4):423–36. https://doi.org/10.1007/s40259-019-00359-0.CrossRefPubMed

129.

Gulacsi L, Brodszky V, Baji P, Rencz F, Pentek M. The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries. Adv Ther. 2017;34(5):1128–44. https://doi.org/10.1007/s12325-017-0522-y.CrossRefPubMedPubMedCentral

Title: Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review
Authors: Mourad F. Rezk
Burkhard Pieper
Publication date: 01-09-2020
Publisher: Springer Healthcare
Keywords: Infliximab
Rheumatoid Arthritis
Published in: Advances in Therapy / Issue 9/2020
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI: https://doi.org/10.1007/s12325-020-01437-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2020

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652 in First-in-Human and Ascending Multiple Oral Dose Studies in Healthy Subjects

Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study

Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study

Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study

Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis

Postnatal Care of Woman with Rheumatic Diseases

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage